Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy

	Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy
刊名	CHINESE MEDICAL JOURNAL
	2014
卷号	127
关键词	PREVIOUSLY TREATED PATIENTS TYROSINE KINASE INHIBITORS FACTOR RECEPTOR MUTATIONS SKIN RASH ERLOTINIB EFFICACY GEFITINIB EGFR TRIAL BENEFIT ADENOCARCINOMA non-small cell lung cancer icotinib antitumor activity adverse events
ISSN号	0366-6999
其他题名	Efficacy and safety of icotinib in Chinese patients with advanced nonsmall cell lung cancer after failure of chemotherapy
英文摘要	Background The preclinical experiments and several clinical studies showed icotinib, an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in Chinese patients with advanced non-small cell lung cancer (NSCLC) who failed previous chemotherapy. We performed a retrospective study of the efficacy and safety of icotinib monotherapy in a different and more recent sample of Chinese patients.
资助项目	[Zhejiang Provincial Natural Science Foundation of China] ; [Development Center for Medical Science and Technology, Ministry of Health of China]
语种	英语
CSCD记录号	CSCD:5039970
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/50996]
专题	中国科学院合肥物质科学研究院
推荐引用方式 GB/T 7714	. Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy[J]. CHINESE MEDICAL JOURNAL,2014,127.
APA	(2014).Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy.CHINESE MEDICAL JOURNAL,127.
MLA	"Efficacy and safety of icotinib in Chinese patients with advanced non-small cell lung cancer after failure of chemotherapy".CHINESE MEDICAL JOURNAL 127(2014).